Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast ...
The Malaysian Reserve

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company ...